Estimating heterogeneity of treatment effect in psychiatric clinical trials
Siegel, J. S.; Zhong, J.; Tomioka, S.; Ogirala, A.; Faraone, S. V.; Szabo, S. T.; Koblan, K.; Hopkins, S. C.
Show abstract
Currently, placebo-controlled clinical trials report mean change and effect sizes, which masks information about heterogeneity of treatment effects (HTE). Here, we present a method to estimate HTE and evaluate the null hypothesis (H0) that a drug has equal benefit for all participants (HTE=0). We developed measure termed estimated heterogeneity of treatment effect or eHTE, which estimates variability in drug response by comparing distributions between study arms. This approach was tested across numerous large placebo-controlled clinical trials. In contrast with variance-based methods which have not identified heterogeneity in psychiatric trials, reproducible instances of treatment heterogeneity were found. For example, heterogeneous response was found in a trial of venlafaxine for depression (peHTE=0.034), and two trials of dasotraline for binge eating disorder (Phase 2, peHTE=0.002; Phase 3, 4mg peHTE=0.011; Phase 3, 6mg peHTE=0.003). Significant response heterogeneity was detected in other datasets as well, often despite no difference in variance between placebo and drug arms. The implications of eHTE as a clinical trial outcomes independent from central tendency of the group is considered and the important of the eHTE method and results for drug developers, providers, and patients is discussed.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Longitudinal impact of different treatment sequences of second-generation antipsychotics on metabolic outcomes: a study using targeted maximum likelihood estimation 92%
- Antipsychotic Polypharmacy and Adverse Drug Reactions Among Adults in a London Mental Health Service, 2008-2018 92%
- Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank 92%
Similar papers in this journal
- Differential Treatment Benefit Prediction For Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data 96%
- Aberrant perception of environmental volatility during social learning in emerging psychosis 92%
- Computational Mechanisms of Approach-Avoidance Conflict Predictively Differentiate Between Affective and Substance Use Disorders 91%
Similar papers in this journal
Similar papers in this journal
- On the treatment effect heterogeneity of antidepressants in major depression. A Bayesian meta-analysis 93%
- Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder: Protocol for a Randomized Controlled Trial 92%
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 91%
Similar papers in this journal
- Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems 93%
- Near, far, wherever you are: Phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature. 91%
- Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.